Building on this approach, transferrin-modified solid lipid nanoparticles co-encapsulated with doxorubicin and plasmid DNA (T-SLN/DE) were formulated to facilitate both gene and drug co-delivery to lung cancer cells. Here, TF is linked to lung cancer.